A Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
Sponsor: Novartis.
The goal of this trial is to provide evidence on the effects of inclisiran versus placebo on cardiovascular events in participants with established atherosclerotic cardiovascular disease who have elevated LDL-C leverl despite being on a high-intensity statin.
Study Team:
Project Manager: A. Branderhorst
Sub investigator: J. Tiebesl, K. Ricken